Skip to main content
Mijn bibliotheek
Shop
Nieuws Boeken Tijdschriften E-learning Web-tv Video Audio
Tips voor Mijn BSL
UITGEBREID ZOEKEN
Inloggen
Top
Quality of Life Research
Gepubliceerd in: Quality of Life Research 2/2014

01-03-2014

Development and initial psychometric evaluation of the hepatitis C virus-patient-reported outcomes (HCV-PRO) instrument

Auteurs: Roger T. Anderson, Robert W. Baran, Birgitta Dietz, Eric Kallwitz, Pennifer Erickson, Dennis A. Revicki

Gepubliceerd in: Quality of Life Research | Uitgave 2/2014

Log in om toegang te krijgen
share
DELEN

Deel dit onderdeel of sectie (kopieer de link)

  • Optie A:
    Klik op de rechtermuisknop op de link en selecteer de optie “linkadres kopiëren”
  • Optie B:
    Deel de link per e-mail
    Link delen
publish
Publiceer nu

Abstract

Background

Chronic hepatitis C virus (HCV) infection is an important public health issue owing to its worldwide prevalence and its profound effects on patients’ well-being and function. We developed a new patient self-report tool, the HCV patient-reported outcomes (HCV-PRO) instrument, to assess patients’ function and well-being reflecting both HCV disease and treatment burdens.

Methods

Items were developed through a qualitative phase including scientific literature review, expert appraisal, and semi-structured patient interviews. The item pool was initially psychometrically tested in 60 adult HCV patients, 18 years of age or older at a university hepatology clinic. A final psychometric test was conducted in 241 members of the online Harris International Panel to examine scale reliability, confirm factor structure, and assess convergent and discriminant validity.

Results

A single-factor 16-item HCV-PRO instrument demonstrated good model fit. The HCV-PRO items and total score (range 0–100) showed excellent item response (few floor and ceiling effects) and reliability (alpha > 0.90). Convergent validity was established from moderate to high (r > 0.50) correlation with symptom burden, life satisfaction (ladder of life), and SF-36v2 scales scores. Mean HCV-PRO scores differentiated between currently treated patients, those previously treated, and patients never treated (p < 0.01), suggesting strong known-groups validity.

Conclusions

The results provide initial evidence that the HCV-PRO can yield reliable and valid measurement of the effects of HCV and its treatment on the well-being and function of HCV-infected patients.
vorige artikel How to measure quality of life in shared-housing arrangements? A comparison of dementia-specific instruments
volgende artikel Cross-cultural adaptation and validation of the Manchester Foot Pain and Disability Index into Spanish
Literatuur
1.
2.
Davis, G. L., Alter, M. J., El-Serag, H., Poynard, T., & Jennings, L. W. (2010). Aging of hepatitis C virus (HCV)-infected persons in the United States: A multiple cohort model of HCV prevalence and disease progression. Gastroenterology, 138, 513–521.PubMedCrossRef
3.
Ware, J. E, Jr, Bayliss, M. S., Mannocchia, M., & Davis, G. L. (1999). Health-related quality of life in chronic hepatitis C: Impact of disease and treatment response. The Interventional Therapy Group. Hepatology, 30, 550–555.PubMedCrossRef
4.
Bayliss, M. S., Gandek, B., Bungay, K. M., Sugano, D., Hsu, M. A., & Ware, J. E, Jr. (1998). A questionnaire to assess the generic and disease-specific health outcomes of patients with chronic hepatitis C. Quality of Life Research, 7, 39–55.PubMedCrossRef
5.
Gremion, C., & Cerny, A. (2005). Hepatits C virus and the immune system: A concise review. Reviews in Medical Virology, 15, 235–268.PubMedCrossRef
6.
Hsu, P., & Federico, C. A. (2012). Health utilities and psychometric quality of life in patients with early- and late-stage hepatitis C virus infection. Journal of Gastroenterology and Hepatology, 27, 149–157.PubMedCrossRef
7.
Younossi, Z., Kallman, J., & Kincaid, J. (2007). The effects of HCV infection and management on health-related quality of life. Hepatology, 45, 806–816.PubMedCrossRef
8.
Smith, B. D., Morgan, R. L., Beckett, G. A., et al. (2012). Centers for Disease Control and Prevention. Recommendations for the identification of chronic hepatitis C virus infection among persons born during 1945–1965. MMWR Recommendations and Reports 61(No. RR-4): 1–36.
9.
Ghany, M. G., Strader, D. B., Thomas, D. L., & Seeff, L. B. (2009). Diagnosis, management, and treatment of hepatitis C: An update. Hepatology, 49, 1335–1374.PubMedCrossRef
10.
11.
12.
Siebert, U., & Sroczynski, G. (2005). Effectiveness and cost-effectiveness of initial combination therapy with interferon/peginterferon plus ribavirin in patients with chronic hepatitis C in Germany: A health technology assessment commissioned by the German federal ministry of health and social security. International Journal of Technology Assessment in Health Care, 21(1), 55–65.
13.
Younossi, Z. M., Aggarwal, J., Martin, M., et al. (2012). Health-related quality-of-life among genotype 1 treatment-naïve chronic hepatitis C patients receiving telaprevir combination treatment: Post hoc analyses of data from the ADVANCE trial. Journal of Hepatology, 56(Suppl 2), S462–S463.CrossRef
14.
Younossi, Z. M., Aggarwal, J., Martin, M., et al. (2012b). Health-related quality-of-life among genotype 1 treatment-naïve chronic hepatitis C patients receiving telaprevir combination treatment: Post hoc analyses of data from the ADVANCE trial. Gastroenterology 142(Suppl 5): S-955. [Abstract Sa1048].
15.
Welsch, C., Jesudian, A., Zeuzem, S., & Jacobson, I. (2012). New direct-acting antiviral agents for the treatment of hepatitis C virus infection and perspectives. Gut, 61(suppl 1), i36–i46.PubMedCrossRef
16.
Food and Drug Administration. (2009). Guidance for industry on patient-reported outcome measures: Use in medical product development to support labeling claims. Federal Register, 74, 65132–65133.
17.
Guest, G., Bunce, A., & Johnson, L. (2006). How many interviews are enough? An experiment with data saturation and variability. Field Methods, 18(1), 59–82.CrossRef
18.
Shumaker, S. A., Berzon, R., & Hays, R. (Eds.). (1993). Special issue. International use, application and performance of health-related quality of life instruments. Quality of Life Research, 2(6), 367–368.
19.
Brod, M., Tesler, L. E., & Christensen, T. L. (2009). Qualitative research and content validity: Developing best practices based on science and experience. Quality of Life Research, 18, 1263–1278.PubMedCrossRef
20.
Ware, J. E, Jr, Kosinski, M., Bjorner, J. B., Turner-Bowker, D. M., Gandek, B., & Maruish, M. E. (2007). User’s manual for the SF-36v2 health survey (2nd ed.). Lincoln: Quality Metric Incorporated.
21.
Cantril, H. (1965). The pattern of human concerns. New Brubswick: Rutgers University Press.
22.
Spiegel, B. M., Younossi, Z. M., Hays, R. D., Revicki, D., Robbins, S., & Kanwal, F. (2005). Impact of hepatitis C on health related quality of life: A systematic review and quantitative assessment. Hepatology, 41, 790–800.PubMedCrossRef
23.
Hollander, A., Foster, G. R., & Weiland, O. (2006). Health-related quality of life before, during and after combination therapy with interferon and ribavirin in unselected Swedish patients with chronic hepatitis C. Scandinavian Journal of Gastroenterology, 41(5), 577–585.PubMedCrossRef
24.
Bernstein, D., Kleinman, L., Barker, C. M., Revicki, D. A., & Green, J. (2002). Relationship of health-related quality of life to treatment adherence and sustained response in chronic hepatitis C patients. Hepatology (Baltimore, Md.), 35(3), 704–708.CrossRef
25.
Mathews, A., Peiffer, L. P., Rhoades, K., & McGarrity, T. J. (2006). Improvement in quality of life measures in patients with refractory hepatitis C, responding to re-treatment with Pegylated interferon alpha -2b and ribavirin. Health and Quality of Life Outcomes, 4, 30.CrossRef
26.
Kang, S.-C., Hwang, S.-J., Lee, S.-H., Chang, F.-Y., & Lee, S.-D. (2005). Health-related quality of life and impact of antiviral treatment in Chinese patients with chronic hepatitis C in Taiwan. World Journal of Gastroenterology: WJG, 11(47), 7494–7498.PubMed
27.
Hassanein, T., Cooksley, G., Sulkowski, M., et al. (2004). The impact of peginterferon alfa-2a plus ribavirin combination therapy on health-related quality of life in chronic hepatitis C. Journal of Hepatology, 40(4), 675–681.PubMedCrossRef
28.
Nunnally, J. C., & Berstain, I. H. (1994). Psychometric theory (3rd ed.). New York: McGraw-Hill.
29.
Wiggins, J. S. (1973). Personality and prediction: Principles of personality assessment. Reading, MA: Addison-Wesley.
30.
MacCallum, R. (1986). Specification searches in covariance structure analysis. Psychological Bulletin, 100, 107–210.CrossRef
31.
Bentler, P., & Bonnett, D. (1980). Significance tests and goodness of fit in the analysis of covariance structures. Psychological Bulletin, 88, 588–606.CrossRef
32.
Bentler, P. (1990). Comparative fit indices in structural models. Psychological Bulletin, 107, 238–246.PubMedCrossRef
33.
Bonkovsky, H. L., & Woolley, J. M. (1999). Consensus interferon study group. Reduction of health-related quality of life in chronic hepatitis C and improvement with interferon therapy. Hepatology, 29, 264–270.PubMedCrossRef
34.
Gralnek, I. M., Hays, R. D., Kilbourne, A., Rosen, H. R., Keeffe, E. B., Artinian, L., et al. (2000). Development and evaluation of the liver disease quality of life instrument in persons with advanced, chronic liver disease: The LDQOL 1.0. American Journal of Gastroenterology, 95(12), 3552–3565.PubMed
35.
Shumaker, S. A., Anderson, R. T., & Czajkowski, S. M. (1990). Psychological tests and scales. In B. Spilker (Ed.), Quality of life assessments in clinical trials (pp. 95–114). New York: Raven Press.
36.
Kleinman, L., Mannix, S., Yuan, Y., Kummer, S., L’Italien, G., & Revicki, D. (2012). Review of patient-reported outcome measures in chronic hepatits C. Health and Quality of Life Outcomes, 10, 92.PubMedCentralPubMedCrossRef
Metagegevens
Titel
Development and initial psychometric evaluation of the hepatitis C virus-patient-reported outcomes (HCV-PRO) instrument
Auteurs
Roger T. Anderson
Robert W. Baran
Birgitta Dietz
Eric Kallwitz
Pennifer Erickson
Dennis A. Revicki
Publicatiedatum
01-03-2014
Uitgeverij
Springer International Publishing
Gepubliceerd in
Quality of Life Research / Uitgave 2/2014
Print ISSN: 0962-9343
Elektronisch ISSN: 1573-2649
DOI
https://doi.org/10.1007/s11136-013-0505-7

Andere artikelen Uitgave 2/2014

Quality of Life Research 2/2014 Naar de uitgave

OriginalPaper

Associations of cancer and other chronic medical conditions with SF-6D preference-based scores in Medicare beneficiaries

OriginalPaper

Physical activity and quality of life among university students: exploring self-efficacy, self-esteem, and affect as potential mediators

Brief Communication

The quality of life questionnaire EQ-5D-5L: psychometric properties and normative values for the general German population

OriginalPaper

Thirty down, only ten to go?! Awareness and influence of a 10-year time frame in TTO

OriginalPaper

How good is “very good”? Translation effect in the racial/ethnic variation in self-rated health status

OriginalPaper

Mapping scores from the Strengths and Difficulties Questionnaire (SDQ) to preference-based utility values